- Report
- March 2025
- 197 Pages
Global
From €3222EUR$3,545USD£2,759GBP
€3580EUR$3,939USD£3,066GBP
- Report
- February 2025
- 200 Pages
Global
From €4081EUR$4,490USD£3,495GBP
- Report
- February 2025
- 200 Pages
Global
From €4081EUR$4,490USD£3,495GBP
- Report
- May 2024
- 136 Pages
Global
From €5907EUR$6,499USD£5,058GBP
- Report
- May 2024
- 134 Pages
Global
From €5907EUR$6,499USD£5,058GBP
- Report
- October 2024
- 244 Pages
Global
From €7226EUR$7,950USD£6,187GBP
- Report
- August 2019
- 30 Pages
China
From €2000EUR$2,200USD£1,712GBP
- Report
- April 2023
- 224 Pages
Global
From €6817EUR$7,500USD£5,837GBP
- Clinical Trials
- April 2024
- 60 Pages
Global
From €1136EUR$1,250USD£973GBP
- Report
- December 2023
- 77 Pages
Global
From €3177EUR$3,495USD£2,720GBP
- Drug Pipelines
- January 2019
- 163 Pages
Global
From €19997EUR$22,000USD£17,122GBP
- Report
- July 2018
- 14 Pages
Global
From €9089EUR$10,000USD£7,783GBP
- Report
- April 2023
- 78 Pages
Global
From €3500EUR$4,125USD£3,102GBP
Alteplase is a thrombolytic drug used to treat cardiovascular diseases such as heart attack and stroke. It works by breaking down the clot that is blocking the blood flow to the heart or brain. Alteplase is administered intravenously and is the only thrombolytic drug approved by the US Food and Drug Administration (FDA). It is used in both acute and chronic cardiovascular diseases, and is often used in combination with other drugs. Alteplase is also used to treat pulmonary embolism, deep vein thrombosis, and peripheral arterial occlusion.
Alteplase is available in both generic and branded forms, and is manufactured by several pharmaceutical companies. Some of the companies in the market include Genentech, Boehringer Ingelheim, Pfizer, and Sanofi. Show Less Read more
